GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (CHIX:NYXHb) » Definitions » Net Income Including Noncontrolling Interests

Nyxoah (CHIX:NYXHB) Net Income Including Noncontrolling Interests : €-43.21 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nyxoah Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Nyxoah's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-11.91 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €-43.21 Mil.

Nyxoah Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Nyxoah's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Net Income Including Noncontrolling Interests Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -8.45 -12.25 -27.62 -31.23 -43.21

Nyxoah Quarterly Data
Dec17 Dec18 Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.91 -12.80 -7.61 -10.89 -11.91

Nyxoah Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-43.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyxoah Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Nyxoah's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyxoah (CHIX:NYXHB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (CHIX:NYXHb) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XTAE:ORBI XTAE:FBRT XTAE:BSEN XTAE:TATT XTAE:ISI ISRG XPAR:EL BDX XSWX:ALC TSE:7741 WST OCSE:COLO B RMD TSE:4543 XSWX:STMN BAX XPAR:DIM HOLX TSE:7733 COO
Traded in Other Exchanges
NYXH:USA 5YI:Germany NYXH:Belgium
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Website
https://www.nyxoah.com
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Nyxoah (CHIX:NYXHB) Headlines

No Headlines